GPT and neutropenia: The AEs that were more common with trabectedin on an every 3-week 24-hour infusion schedule than with pazopanib were all-grade and grade 3/4 anemia and neutropenia, all-grade nausea/vomiting, and all-grade and grade 3 elevations in AST and ALT.